GlassScriptPhysician profile
John S Robertson
NPI 1184651770
$1,941.69
in general payments reported to CMS, 2019-2025
22 companies · $383 in 2025
The $383 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $507 · 2020: $91.82 · 2021: $32.28 · 2022: $35.64 · 2023: $329 · 2024: $563 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,275.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $266.91 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $258.26 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $244.17 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $240.35 | 2023-2025 | |
| Astellas Pharma US INC | $140.78 | 2019-2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $117.81 | 2019 | |
| Abbvie INC. | $108.70 | 2019-2025 | Viberzi, Linzess |
| Novo Nordisk INC | $99.31 | 2019-2025 | |
| Abbott Laboratories | $75.07 | 2022-2025 | Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.72 | 2023-2024 | Ofev, Jardiance, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.11 | 2025 | Xifaxan |
| Amgen INC. | $49.56 | 2019 | |
| Tactile Systems Technology INC | $41.38 | 2025 | Flexitouch Plus, Nimbl |
| Glaxosmithkline, LLC. | $32.36 | 2020-2025 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $27.75 | 2020-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $23.27 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $20.64 | 2024 | Voquezna |
| Lundbeck LLC | $19.63 | 2024 | Rexulti |
| Amarin Pharma, INC. | $14.51 | 2019 | |
| Exact Sciences Corporation | $14.41 | 2023 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $12.89 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Robertson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.